# Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures

> **NCT01648101** · PHASE3 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 76 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** Retigabine 900mg/day
- **DRUG:** Retigabine 600mg/day
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01648101
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-08-29
- **Primary completion:** 2013-12-01
- **Final completion:** 2013-12-23
- **Target enrollment:** 76 (ACTUAL)
- **Why stopped:** Registration of the medicine is no longer being pursued in South Korea, Taiwan or Vietnam
- **Last updated:** 2018-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01648101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01648101, "Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01648101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*